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The evaluation of atherosclerosis progression is a key issue in
cardiovascular prevention because it could help in reducing
cardiovascular morbidity and mortality.
In this issue of the European Journal of Nuclear Medicine
and Molecular Imaging, Fayad et al. report on the results of a
prospective substudy of the Dal-Plaque trial [1], which inves-
tigated the efficacy and safety of the cholesteryl ester transfer
protein modulator dalcetrapib. The authors provide evidence
that short-term (6 months) changes in arterial inflammation as
assessed by 18F-fluorodeoxyglucose positron emission to-
mography (FDG-PET) were associated with longer-term
(24 months) structural changes of atherosclerosis evaluated
by MRI. The findings of this study confirm the capacity of
PET to predict structural changes of atherosclerosis demon-
strated by Dal-Plaque, and improve on the results of the orig-
inal study, in which total vessel areas were assessed by MRI,
while in this substudy mean wall area and thickness were
determined. Total vessel area is not fully appropriate to assess
atherosclerosis progression because an increase in the vessel
lumen could theoretically occur without concomitant changes
in wall area or thickness, which are more stringent outcome
measures.
PET has been shown to be sensitive and reproducible in
delineating vascular inflammation in various disorders. In vas-
culitis, a linear, smooth vascular FGD uptake extending over
long vessel segments is typically observed [2]. In contrast,
atherosclerosis is characterized by an irregular, more limited,
Bspotty^ pattern [2], which corresponds to vascular areas more
heavily infiltrated by macrophages, i.e., to unstable atheroma,
which is potentially thrombogenic [3]. Consistent with this
concept, PET has been demonstrated to be able to predict
adverse cardiovascular events [4].
The results of this substudy further strengthen the rel-
evance of arterial inflammation as assessed by PET to
the subsequent development of atherosclerotic changes,
but also raise some questions. First, why did baseline
vascular FDG uptake not predict structural changes at
24 months? The authors claim that the pharmacological
intervention may have acted as confounder, but this ex-
planation conflicts with the observation that dalcetrapib
did not reduce carotid artery inflammation relative to
placebo. Moreover, inflammatory changes at 3 months
also failed to predict later structural changes, suggesting
that the delta between baseline and subsequent inflam-
mation may have greater predictive power for vascular
changes. This would be in keeping with the concept,
well-established in oncology, that changes in tumor
SUV following treatment may have better prognostic val-
ue than baseline SUV [5]. The specific pharmacological
agent investigated may also be relevant to the optimal
time frame required to detect significant inflammatory
changes, which may have implications for future clinical
trials. Another important observation [1] is that inflam-
mation in the carotid arteries appears to be more sensi-
tive than the aorta in predicting structural changes; this
finding, too, may have relevance to future studies on
pharmacological agents for atherosclerosis.
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No association was found in this substudy between chang-
es in biomarkers of inflammation and structural vascular
changes, despite the fact that the C-reactive protein is an
established marker for atherosclerosis progression. This find-
ing suggests that PET has a complementary role to the mea-
surement of inflammatory biomarkers, and specifically that
local inflammation may be more important that systemic in-
flammation to determine future arterial wall abnormalities.
In conclusion, this study underscores the role of PET as a
promising outcome measure in future trials on agents that
target vascular inflammation, although the optimal time points
at which PETshould be performed remain sub judice and may
differ for different agents. As the authors state, assessing vas-
cular inflammation by PETmay facilitate the evaluation of the
efficacy of novel candidate molecules in future clinical trials
and allow investigators to move more confidently to phase III
clinical trials.
References
1. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of
dalcetrapib on atherosclerotic disease using novel non-invasive
multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Lancet. 2011;378(9802):1547–59.
2. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the
diagnosis and follow-up of large-vessel vasculitis: an update.
Rheumatology (Oxford). 2008;47(4):403–8.
3. Buscombe JR. Exploring the nature of atheroma and cardiovascular
inflammation in vivo using positron emission tomography (PET). Br
J Radiol. 2015;88(1053):20140648.
4. Figueroa AL, Abdelbaky A, Truong QA, et al. Measurement of
arterial activity on routine FDG PET/CT images improves prediction
of risk of future CVevents. JACC Cardiovasc Imaging. 2013;6(12):
1250–9.
5. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax
reduction improves early prognosis value of interim positron emis-
sion tomography scans in diffuse large B-cell lymphoma. Blood.
2011;118(1):37–43.
248 Eur J Nucl Med Mol Imaging (2017) 44:247–248
